Pretreatment evaluation of HCV-infected patients is a complex interplay between multiple clinical and viral parameters, leading to a tailored approach that may bring real-life sustained virological response (SVR) rates close to 98%-99%.
Cento, V., Aragri, M., Teti, E., Polilli, E., Bertoli, A., Foroghi, L., et al. (2017). Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY [10.1093/jac/dkx302].
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study
CENTO, VALERIA;TETI, ELISABETTA;BERTOLI, ADA;BARBALISCIA, SILVIA;DI MAIO, VELIA CHIARA;SARMATI, LOREDANA;ANDREONI, MASSIMO;PERNO, CARLO FEDERICO;CECCHERINI SILBERSTEIN, FRANCESCA
2017-09-18
Abstract
Pretreatment evaluation of HCV-infected patients is a complex interplay between multiple clinical and viral parameters, leading to a tailored approach that may bring real-life sustained virological response (SVR) rates close to 98%-99%.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
